Chemotherapy sprayed directly into the abdomen: a new attack on stubborn cancers

NCT ID NCT05277766

First seen Jul 13, 2026 · Last updated Jul 14, 2026 · Updated 1 time

Summary

This phase 1 trial tests a new method of delivering chemotherapy for people with cancers that have spread to the lining of the abdomen (peritoneal carcinomatosis) from gastrointestinal cancers like colorectal, stomach, or pancreatic cancer. The drug, nanoliposomal irinotecan (Onivyde), is given as a pressurized aerosol spray directly into the abdomen during a minimally invasive procedure called PIPAC. The main goal is to find the highest safe dose and to watch for side effects, with a secondary aim of determining a dose for future studies.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
nanoliposomal irinotecan (Onivyde)
What this could lead to
If successful, this could establish a safe dose for a new way to deliver chemotherapy directly to abdominal tumors, potentially improving control of peritoneal carcinomatosis.
What could go wrong
This is an early phase 1 trial with a small number of participants, so the main goal is safety, not proof of effectiveness. The treatment may cause serious side effects or fail to shrink tumors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for APPENDIX CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • UZ Ghent

    Ghent, East-Flanders, 9000, Belgium

More trials for these conditions

Other studies related to the condition(s) this trial covers.